NI201800027A - Anticuerpos anti-bcma, moléculas de unión a antígenos biespecíficas que se unen a bcma y cd3, y usos de estos. - Google Patents

Anticuerpos anti-bcma, moléculas de unión a antígenos biespecíficas que se unen a bcma y cd3, y usos de estos.

Info

Publication number
NI201800027A
NI201800027A NI201800027A NI201800027A NI201800027A NI 201800027 A NI201800027 A NI 201800027A NI 201800027 A NI201800027 A NI 201800027A NI 201800027 A NI201800027 A NI 201800027A NI 201800027 A NI201800027 A NI 201800027A
Authority
NI
Nicaragua
Prior art keywords
bcma
antibodies
antigen
cancer
binding fragments
Prior art date
Application number
NI201800027A
Other languages
English (en)
Spanish (es)
Inventor
Kodandaram Pillarisetti
Thomas Baldwin Eric
D Powers Gordon
Maria Fernandes Cardoso Rosa
Attar Ricardo
Gaudet Francois
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56740579&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201800027(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NI201800027A publication Critical patent/NI201800027A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NI201800027A 2015-08-17 2018-02-16 Anticuerpos anti-bcma, moléculas de unión a antígenos biespecíficas que se unen a bcma y cd3, y usos de estos. NI201800027A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562206246P 2015-08-17 2015-08-17

Publications (1)

Publication Number Publication Date
NI201800027A true NI201800027A (es) 2018-08-30

Family

ID=56740579

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201800027A NI201800027A (es) 2015-08-17 2018-02-16 Anticuerpos anti-bcma, moléculas de unión a antígenos biespecíficas que se unen a bcma y cd3, y usos de estos.

Country Status (41)

Country Link
US (1) US10072088B2 (https=)
EP (3) EP4667058A3 (https=)
JP (4) JP2018525005A (https=)
KR (2) KR102890745B1 (https=)
CN (1) CN108350076B (https=)
AR (2) AR105724A1 (https=)
AU (1) AU2016308567B2 (https=)
BR (1) BR112018003017A2 (https=)
CA (1) CA2995754A1 (https=)
CL (1) CL2018000431A1 (https=)
CO (1) CO2018001524A2 (https=)
CY (2) CY1123297T1 (https=)
DK (1) DK3337824T3 (https=)
EA (1) EA201890513A1 (https=)
EC (1) ECSP18019568A (https=)
ES (1) ES2814550T3 (https=)
FI (1) FIC20230012I1 (https=)
FR (2) FR23C1011I1 (https=)
HR (1) HRP20201375T1 (https=)
HU (2) HUE050556T2 (https=)
IL (3) IL298041B2 (https=)
JO (1) JO3799B1 (https=)
LT (2) LT3337824T (https=)
LU (1) LUC00301I2 (https=)
MA (1) MA53750A (https=)
MX (2) MX2018002043A (https=)
MY (1) MY191325A (https=)
NI (1) NI201800027A (https=)
NL (1) NL301219I2 (https=)
PE (1) PE20180795A1 (https=)
PH (1) PH12018500361A1 (https=)
PL (1) PL3337824T3 (https=)
PT (1) PT3337824T (https=)
RS (1) RS60755B1 (https=)
SI (1) SI3337824T1 (https=)
SV (1) SV2018005634A (https=)
TW (3) TWI777924B (https=)
UA (1) UA127515C2 (https=)
UY (2) UY36859A (https=)
WO (1) WO2017031104A1 (https=)
ZA (1) ZA201801789B (https=)

Families Citing this family (165)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014124280A1 (en) 2013-02-08 2014-08-14 Institute For Myeloma & Bone Cancer Research Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma
GB201317928D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Molecule
BR112017001183A2 (pt) 2014-07-21 2017-11-28 Novartis Ag tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
US9708412B2 (en) 2015-05-21 2017-07-18 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
MX2018002043A (es) * 2015-08-17 2018-07-06 Janssen Pharmaceutica Nv ANTICUERPOS ANTI-BCMA, MOLí‰CULAS DE UNIí“N A ANTíGENOS BIESPECíFICAS QUE SE UNEN A BCMA Y CD3, Y USOS DE ESTOS.
ES2898329T3 (es) 2016-01-12 2022-03-07 Oncotracker Inc Métodos mejorados para supervisar el estado inmunitario de un sujeto
EA201891753A1 (ru) 2016-02-03 2019-01-31 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкции антител к psma и cd3, вовлекающие т-клетки
CN108778329B (zh) 2016-02-17 2022-09-16 西雅图基因公司 Bcma抗体和其用以治疗癌症和免疫病症的用途
MX392069B (es) * 2016-05-09 2025-03-21 Bristol Myers Squibb Co Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos.
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
EP3493844A4 (en) 2016-05-20 2021-03-24 Harpoon Therapeutics Inc. SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN
US20190233533A1 (en) 2016-06-28 2019-08-01 Umc Utrecht Holding B.V. Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
TWI781108B (zh) 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
PE20241349A1 (es) 2016-09-14 2024-07-03 Teneobio Inc Anticuerpos de union a cd3
IL317134A (en) 2016-12-21 2025-01-01 Teneobio Inc An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation
EP3567049A4 (en) 2016-12-28 2020-08-26 Green Cross Lab Cell Corporation CHEMERICAL ANTIGENIC RECEPTOR AND NATURAL KILLER CELLS EXPRESSING THE SAME
CN110582509A (zh) 2017-01-31 2019-12-17 诺华股份有限公司 使用具有多特异性的嵌合t细胞受体蛋白治疗癌症
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3621994A4 (en) 2017-05-12 2020-12-30 Harpoon Therapeutics, Inc. MESOTHELIN BINDING PROTEINS
US11635435B2 (en) 2017-06-13 2023-04-25 Oncotracker, Inc. Diagnostic, prognostic, and monitoring methods for solid tumor cancers
KR20250007003A (ko) 2017-06-20 2025-01-13 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
CN110945026B (zh) * 2017-06-20 2024-03-19 特纳奥尼股份有限公司 仅有重链的抗bcma抗体
WO2019000223A1 (en) * 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
MA51447A (fr) * 2017-08-01 2020-06-10 Medimmune Llc Conjugué anticorps monoclonal-médicament dirigé contre bcma
WO2019035938A1 (en) * 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
JP7385556B2 (ja) * 2017-09-01 2023-11-22 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｂｃｍａ抗原に特異的な免疫原性ペプチドおよびその使用
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
MX2020003915A (es) * 2017-10-13 2020-10-08 Harpoon Therapeutics Inc Proteinas trispecificas y metodos de uso.
AU2018351050B2 (en) 2017-10-18 2025-09-18 Novartis Ag Compositions and methods for selective protein degradation
SG11202003501XA (en) * 2017-11-01 2020-05-28 Juno Therapeutics Inc Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
PT3703750T (pt) 2017-11-01 2025-01-17 Memorial Sloan Kettering Cancer Center Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes
MX2020004568A (es) 2017-11-06 2020-10-05 Juno Therapeutics Inc Combinación de una terapia celular y un inhibidor de gamma secretasa.
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
CN111787938A (zh) 2017-11-15 2020-10-16 诺华股份有限公司 靶向bcma的嵌合抗原受体、靶向cd19的嵌合抗原受体及组合疗法
US20200371091A1 (en) 2017-11-30 2020-11-26 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
US12539308B2 (en) 2018-01-08 2026-02-03 The Trustees Of The University Of Pennsylvania Immune-enhancing RNAs for combination with chimeric antigen receptor therapy
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
AU2019215031C1 (en) 2018-01-31 2026-02-26 Novartis Ag Combination therapy using a chimeric antigen receptor
US20200399383A1 (en) 2018-02-13 2020-12-24 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2019190969A1 (en) * 2018-03-26 2019-10-03 Sutro Biopharma, Inc. Anti-bcma receptor antibodies, compositions comprising anti bcma receptor antibodies and methods of making and using anti-bcma antibodies
CA3095373A1 (en) * 2018-04-13 2019-10-17 Affimed Gmbh Nk cell engaging antibody fusion constructs
BR112020023330A2 (pt) 2018-05-14 2021-04-20 Harpoon Therapeutics, Inc. porção de ligação para ativação condicional de moléculas de imunoglobulina
UA130542C2 (uk) * 2018-05-16 2026-03-18 Янссен Байотек, Інк. Антитіло до cd38 та терапевтичний засіб, який перенаправляє т-клітини, для лікування множинної мієломи у суб'єкта
KR102870868B1 (ko) * 2018-06-01 2025-10-15 노파르티스 아게 Bcma에 대한 결합 분자 및 이의 용도
TWI890660B (zh) 2018-06-13 2025-07-21 瑞士商諾華公司 Bcma 嵌合抗原受體及其用途
JP7357012B2 (ja) 2018-06-14 2023-10-05 ２セブンティ バイオ インコーポレイテッド 抗ｂｃｍａ ｃａｒ抗体、コンジュゲート、および使用方法
EP3777895A4 (en) 2018-06-26 2021-12-22 ABL Bio Inc. ANTI-BCMA ANTIBODIES AND ASSOCIATED USE
CA3105448A1 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
TWI838389B (zh) * 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
MD3823665T2 (ro) 2018-07-19 2024-05-31 Regeneron Pharma Receptori antigenci chimerici cu specificitate BCMA și utilizările acestora
CA3105729A1 (en) * 2018-07-31 2020-02-06 Amgen Research (Munich) Gmbh Dosing regimen for bcma-cd3 bispecific antibodies
EP3833392A4 (en) 2018-08-08 2022-05-18 Dragonfly Therapeutics, Inc. MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE
EP3844265A2 (en) 2018-08-31 2021-07-07 Novartis AG Methods of making chimeric antigen receptor-expressing cells
EP4635978A2 (en) 2018-08-31 2025-10-22 Novartis AG Methods of making chimeric antigen receptor-expressing cells
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
US12116415B2 (en) 2018-10-09 2024-10-15 Single Cell Technology, Inc. Anti-BCMA antibodies
MA54078A (fr) 2018-11-01 2021-09-15 Juno Therapeutics Inc Méthodes pour le traitement au moyen de récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
JP7410143B2 (ja) * 2018-11-01 2024-01-09 山▲東▼新▲時▼代▲薬▼▲業▼有限公司 二重特異性抗体及びその用途
CN121405815A (zh) * 2018-12-19 2026-01-27 希望之城 Baff-r双特异性t细胞衔接子抗体
BR112021014662A2 (pt) * 2019-02-01 2021-09-21 Glaxosmithkline Intellectual Property Development Limited Tratamentos de combinação para o câncer que compreendem belantamab mafodotin e um anticorpo anti ox40 e usos e métodos dos mesmos
GB2599228B (en) 2019-02-21 2024-02-07 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof
CN119039441A (zh) 2019-02-21 2024-11-29 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
US20220152150A1 (en) 2019-02-25 2022-05-19 Novartis Ag Mesoporous silica particles compositions for viral delivery
KR20210133261A (ko) * 2019-02-26 2021-11-05 소렌토 쎄라퓨틱스, 인코포레이티드 Bcma에 결합하는 항원 결합 단백질
EP3941938A1 (en) 2019-03-06 2022-01-26 Dana-Farber Cancer Institute, Inc. T cell receptors specific to b-cell maturation antigen for treatment of cancer
CA3132587A1 (en) 2019-03-21 2020-09-24 Regeneron Pharmaceuticals, Inc. Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
EP3942025A1 (en) 2019-03-21 2022-01-26 Novartis AG Car-t cell therapies with enhanced efficacy
WO2020206330A1 (en) 2019-04-05 2020-10-08 Teneobio, Inc. Heavy chain antibodies binding to psma
EP3953455A1 (en) 2019-04-12 2022-02-16 Novartis AG Methods of making chimeric antigen receptor-expressing cells
EP3959320A1 (en) 2019-04-24 2022-03-02 Novartis AG Compositions and methods for selective protein degradation
EP3733707A1 (en) * 2019-04-30 2020-11-04 Celyad S.A. Car t-cells targeting bcma and uses thereof
JP2022531001A (ja) * 2019-05-03 2022-07-05 セルジーン コーポレーション 抗ｂｃｍａ抗体コンジュゲート、そのコンジュゲートを含む組成物ならびにそのコンジュゲートの製造および使用方法
AU2020275002A1 (en) 2019-05-14 2021-12-23 Harpoon Therapeutics, Inc. EpCAM binding proteins and methods of use
JP7489407B2 (ja) 2019-05-21 2024-05-23 ノバルティス アーゲー Ｃｄ１９結合分子及びその使用
CR20210622A (es) 2019-06-14 2022-06-27 Teneobio Inc Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
CN110229232B (zh) * 2019-06-19 2020-05-19 北京智仁美博生物科技有限公司 双特异性抗体及其用途
MX2022001065A (es) * 2019-07-30 2022-02-14 Shanghai Hansoh Biomedical Co Ltd Anticuerpo anti-bcma, fragmento de union al antigeno y uso medico del mismo.
WO2021092060A1 (en) * 2019-11-05 2021-05-14 Engmab Sarl Methods of treatment
LT3819007T (lt) 2019-11-11 2024-10-10 Amgen Research (Munich) Gmbh Dozavimo režimas, skirtas anti-bcma agentams
IL293215A (en) 2019-11-26 2022-07-01 Novartis Ag Chimeric antigen receptors that bind bcma and cd19 and their uses
CN114929343B (zh) * 2019-12-06 2025-03-18 瑞泽恩制药公司 用双特异性抗BCMA x抗CD3抗体治疗多发性骨髓瘤的方法
CA3160765A1 (en) * 2019-12-10 2021-06-17 Abl Bio, Inc. Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof
WO2021132746A1 (en) * 2019-12-24 2021-07-01 Abl Bio, Inc. Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof
CN114929277A (zh) 2019-12-16 2022-08-19 2赛文缇生物公司 抗bcma car抗体、缀合物及使用方法
WO2021136308A1 (en) * 2020-01-03 2021-07-08 Biosion Inc. Antibodies binding bcma and uses thereof
AU2020416273A1 (en) 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
EP4110376A2 (en) 2020-02-27 2023-01-04 Novartis AG Methods of making chimeric antigen receptor-expressing cells
CN115397460A (zh) 2020-02-27 2022-11-25 诺华股份有限公司 制备表达嵌合抗原受体的细胞的方法
IL296358A (en) * 2020-03-13 2022-11-01 Janssen Biotech Inc Materials and methods for modulating delta chain mediated immunity
TW202144425A (zh) * 2020-04-17 2021-12-01 大陸商上海翰森生物醫藥科技有限公司 特異性抗原結合分子，其製備方法及醫藥用途
IL297601A (en) * 2020-04-29 2022-12-01 Teneobio Inc Multispecific heavy chain antibodies with modified heavy chain constant regions
TW202330622A (zh) * 2020-04-29 2023-08-01 美商泰尼歐生物公司 具有經修飾重鏈恆定區之多特異性重鏈抗體
CN113637073B (zh) * 2020-05-11 2024-04-12 上海赛比曼生物科技有限公司 Bcma抗体及其制备和应用
JP2023524875A (ja) * 2020-05-11 2023-06-13 ヤンセン バイオテツク，インコーポレーテツド 多発性骨髄腫を治療するための方法
BR112022023392A2 (pt) 2020-05-19 2022-12-20 Janssen Biotech Inc Composições que compreendem um agente terapêutico de redirecionamento de células t e um inibidor da via de adesão de vla-4
JP2023529211A (ja) 2020-06-11 2023-07-07 ノバルティス アーゲー Ｚｂｔｂ３２阻害剤及びその使用
JP7620780B2 (ja) * 2020-06-30 2025-01-24 ノナ・バイオサイエンシーズ・（シャンハイ）・カンパニー・リミテッド Ｈ２Ｌ２とＨＣＡｂ構造を有する結合タンパク質
CN116472049A (zh) 2020-06-30 2023-07-21 特尼奥生物股份有限公司 与bcma结合的多特异性抗体
CN114075287B (zh) 2020-08-18 2023-07-21 湖南远泰生物技术有限公司 人源化bcma抗体和bcma-car-t细胞
MX2023002107A (es) 2020-08-21 2023-03-15 Novartis Ag Composiciones y metodos para la generacion in vivo de celulas que expresan car.
WO2022053990A1 (en) * 2020-09-14 2022-03-17 Pfizer Inc. Methods, therapies and uses for treating cancer
MX2023003041A (es) 2020-09-16 2023-05-09 Amgen Inc Métodos para administrar dosis terapéuticas de moléculas de acoplamiento a células t biespecíficas para el tratamiento de cáncer.
US20240002539A1 (en) * 2020-11-03 2024-01-04 Ab Studio Inc. Multispecific antibodies and uses thereof
EP4240756A1 (en) 2020-11-04 2023-09-13 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
CN114524878B (zh) * 2020-11-23 2024-08-02 康诺亚生物医药科技（成都）有限公司 一种双特异性抗体及其用途
CN114573703A (zh) * 2020-12-02 2022-06-03 康诺亚生物医药科技（成都）有限公司 一种t细胞衔接器治疗剂的开发和应用
WO2022135468A1 (zh) * 2020-12-23 2022-06-30 信达生物制药(苏州)有限公司 抗bcma×cd3双特异性抗体及其用途
AU2022214319A1 (en) 2021-01-28 2023-08-03 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome
JP2024507180A (ja) 2021-02-16 2024-02-16 ヤンセン ファーマシューティカ エヌ．ベー． Ｂｃｍａ、ｇｐｒｃ５ｄ、及びｃｄ３を標的とする三重特異的抗体
US12162945B2 (en) 2021-03-05 2024-12-10 Immunome, Inc. EPHA2 antibodies
JP7714675B2 (ja) 2021-03-24 2025-07-29 ヤンセン バイオテツク，インコーポレーテツド ＣＤ７９ｂ、ＣＤ２０、及びＣＤ３を標的とする三重特異性抗体
WO2022216993A2 (en) 2021-04-08 2022-10-13 Marengo Therapeutics, Inc. Multifuntional molecules binding to tcr and uses thereof
WO2022229853A1 (en) 2021-04-27 2022-11-03 Novartis Ag Viral vector production system
WO2022232488A1 (en) 2021-04-30 2022-11-03 Celgene Corporation Combination therapies using an anti-bcma antibody drug conjugate (adc) in combination with a gamma secretase inhibitor (gsi)
TW202309522A (zh) 2021-05-11 2023-03-01 美商健生生物科技公司 用於監測復發性及／或難治性多發性骨髓瘤之治療的方法及組成物
EP4347039A1 (en) 2021-05-28 2024-04-10 Janssen Biotech, Inc. Bcma as a target for t cell redirecting antibodies in b cell lymphomas
CN115521381B (zh) * 2021-06-24 2024-10-29 益科思特(北京)医药科技发展有限公司 结合bcma和cd3的双特异性抗体及其制备方法与应用
CN115569191A (zh) * 2021-07-05 2023-01-06 山东新时代药业有限公司 一种重组人源化抗bcma/cd3双特异性抗体冻干制剂
WO2023020474A1 (en) * 2021-08-16 2023-02-23 Utc Therapeutics (Shanghai) Co., Ltd. Bcma targetting antibodies and uses thereof in cancer therapies
EP4388000A1 (en) 2021-08-20 2024-06-26 Novartis AG Methods of making chimeric antigen receptor?expressing cells
JP2024537991A (ja) 2021-10-14 2024-10-18 アーセナル バイオサイエンシズ インコーポレイテッド 共発現されるｓｈＲＮＡと論理ゲートシステムとを有する免疫細胞
EP4423141A4 (en) * 2021-10-27 2025-12-17 Janssen Biotech Inc METHOD FOR IMPROVED BCMA IMMUNOHISTOCHEMIC DETECTION IN HUMAN AND APE TISSUE
AU2022380155A1 (en) 2021-11-03 2024-06-20 Janssen Biotech, Inc. Corticosteriod reduction in treatment with anti-cd38 antibodies
MX2024005392A (es) 2021-11-03 2024-08-06 Janssen Biotech Inc Métodos para tratar cánceres y potenciar la eficacia de anticuerpos biespecíficos para bcmaxcd3.
KR20240099432A (ko) * 2021-11-10 2024-06-28 얀센 바이오테크 인코포레이티드 이중특이성 bcma/cd3 항체를 포함하는 안정한 제형
WO2023098846A1 (zh) * 2021-12-03 2023-06-08 江苏先声药业有限公司 抗bcma纳米抗体及其应用
EP4507790A1 (en) 2022-04-11 2025-02-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
CN117003871A (zh) 2022-04-28 2023-11-07 北京天广实生物技术股份有限公司 结合bcma和cd3的抗体及其用途
CN116023504B (zh) * 2022-06-07 2025-09-30 江苏蒙彼利生物科技有限公司 双特异性嵌合抗原受体（car）及其制备方法
AU2023369684A1 (en) 2022-10-26 2025-04-17 Novartis Ag Lentiviral formulations
KR20250097946A (ko) 2022-11-02 2025-06-30 얀센 바이오테크 인코포레이티드 암을 치료하는 방법
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
WO2024119126A1 (en) * 2022-12-02 2024-06-06 Artiva Biotherapeutics, Inc. Anti-bcma antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
CN117186229B (zh) * 2022-12-06 2024-03-29 成都赛恩吉诺生物科技有限公司 具有长cdr3序列的抗人bcma纳米抗体及car-t和应用
WO2024124088A1 (en) * 2022-12-09 2024-06-13 Sana Biotechnology, Inc. Bcma-specific antibody constructs and compositions thereof
CN120857940A (zh) 2023-02-17 2025-10-28 瑞泽恩制药公司 对cd3/taa双特异性抗体有反应的诱导型nk细胞
AU2024239150A1 (en) 2023-03-21 2025-10-02 Biograph 55, Inc. Cd19/cd38 multispecific antibodies
US20250242019A2 (en) * 2023-04-19 2025-07-31 Janssen Biotech, Inc. Methods for treating multiple myeloma
WO2024231860A1 (en) 2023-05-09 2024-11-14 Janssen Biotech, Inc. Pharmaceutical compositions comprising a bispecific bcma/cd3 antibody at high concentration
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
TW202502826A (zh) 2023-06-06 2025-01-16 大陸商信達生物製藥（蘇州）有限公司 抗ｇｐｒｃ５ｄ／ｂｃｍａ／ｃｄ３三特異性抗體的製備及其用途
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025094107A1 (en) 2023-11-01 2025-05-08 Janssen Biotech, Inc. Methods for treating high-risk smoldering multiple myeloma
WO2025096717A1 (en) * 2023-11-01 2025-05-08 Janssen Biotech, Inc. Methods for treating multiple myeloma
WO2025131075A1 (zh) * 2023-12-21 2025-06-26 上海君实生物医药科技股份有限公司 抗cd3和抗cd3多特异性抗体及用途
WO2025160324A2 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
US20250242018A1 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
US20250276092A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025231372A2 (en) 2024-05-03 2025-11-06 Janssen Biotech, Inc. Methods for treating multiple myeloma with car-t cells and bispecific antibodies
WO2025243241A1 (en) 2024-05-23 2025-11-27 Janssen Biotech, Inc. Methods for treating multiple myeloma
WO2026033437A1 (en) 2024-08-07 2026-02-12 Janssen Biotech, Inc. Methods of treating autoimmune diseases comprising the administration of anti-bcma therapeutics
WO2026050572A2 (en) 2024-08-29 2026-03-05 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof
WO2026072671A1 (en) 2024-09-24 2026-04-02 City Of Hope Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1015576E (pt) 1997-09-16 2005-09-30 Egea Biosciences Llc Metodo para a sintese quimica completa e montagem de genes e de genomas
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
WO2001024812A1 (en) 1999-10-06 2001-04-12 N.V. Nutricia USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA
WO2002066516A2 (en) 2001-02-20 2002-08-29 Zymogenetics, Inc. Antibodies that bind both bcma and taci
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
EP1940881B1 (en) 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
WO2007117600A2 (en) 2006-04-07 2007-10-18 Macrogenics, Inc. Combination therapy for treating autoimmune diseases
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
RS53008B2 (sr) 2007-04-03 2022-12-30 Amgen Res Munich Gmbh Interspecijski specifičan cd3-epsilon vezujući domen
MX2009010611A (es) 2007-04-03 2010-03-26 Micromet Ag Enlazadores biespecificos, especificos para especies.
RU2769948C2 (ru) 2007-04-03 2022-04-11 Эмджен Рисерч (Мьюник) Гмбх CD3-Эпсилон-связывающий домен с межвидовой специфичностью
CA2720682A1 (en) 2008-04-25 2009-10-29 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
EP2352765B1 (en) 2008-10-01 2018-01-03 Amgen Research (Munich) GmbH Cross-species-specific single domain bispecific single chain antibody
US20110293619A1 (en) 2008-10-01 2011-12-01 Micromet Ag CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY
DK2352763T4 (da) 2008-10-01 2022-10-17 Amgen Res Munich Gmbh Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener
ES2705714T3 (es) 2008-10-31 2019-03-26 Janssen Biotech Inc Métodos y usos de dominio de Fibronectina tipo III basado en estructuras de composiciones
BRPI1008532B1 (pt) 2009-02-12 2021-12-14 Janssen Biotech, Inc Arcabouço de proteína isolada, método para construção de uma biblioteca de arcabouço de proteína isolada, molécula de ácido nucleico isolada, vetor de ácido nucleico isolado, célula hospedeira de bactéria ou fungo, composição, dispositivo médico e artigo de manufatura para uso farmacêutico ou de diagnóstico em seres humanos
MX341884B (es) 2009-03-10 2016-09-07 Biogen Ma Inc Anticuerpos anti-antigeno de maduracion de celulas b (bcma).
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
HRP20241208T1 (hr) 2010-04-20 2024-11-22 Genmab A/S Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
EP3974453A3 (en) 2010-11-16 2022-08-03 Amgen Inc. Agents and methods for treating diseases that correlate with bcma expression
US20130101599A1 (en) 2011-04-21 2013-04-25 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
WO2012158818A2 (en) * 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
CA2880791A1 (en) * 2011-08-03 2013-02-07 Children's Medical Center Corporation A broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin
BR112014010580B1 (pt) 2011-11-04 2021-01-12 Zymeworks, Inc. constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado
TWI679212B (zh) * 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
PT2931030T (pt) 2012-12-14 2020-08-03 Open Monoclonal Tech Inc Polinucleótidos que codificam anticorpos de roedores com idiótipos humanos e animais que os compreendem
EP2762497A1 (en) * 2013-02-05 2014-08-06 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
WO2014122143A1 (en) 2013-02-05 2014-08-14 Engmab Ag Method for the selection of antibodies against bcma
MX2018002043A (es) * 2015-08-17 2018-07-06 Janssen Pharmaceutica Nv ANTICUERPOS ANTI-BCMA, MOLí‰CULAS DE UNIí“N A ANTíGENOS BIESPECíFICAS QUE SE UNEN A BCMA Y CD3, Y USOS DE ESTOS.

Also Published As

Publication number Publication date
JP2018525005A (ja) 2018-09-06
EP4667058A3 (en) 2026-04-01
CY2023007I1 (el) 2023-06-09
TW202307000A (zh) 2023-02-16
CY1123297T1 (el) 2021-12-31
JP2021184721A (ja) 2021-12-09
JP7621324B2 (ja) 2025-01-24
AR105724A1 (es) 2017-11-01
IL298041A (en) 2023-01-01
AU2016308567A1 (en) 2018-03-08
IL257468A (en) 2018-04-30
FR23C1012I1 (fr) 2023-04-14
PL3337824T3 (pl) 2021-04-19
NL301219I1 (https=) 2023-03-01
TW202406935A (zh) 2024-02-16
EP4667058A2 (en) 2025-12-24
FIC20230012I1 (fi) 2023-02-22
IL320478A (en) 2025-06-01
ECSP18019568A (es) 2018-04-30
PH12018500361A1 (en) 2018-09-03
WO2017031104A1 (en) 2017-02-23
TWI777924B (zh) 2022-09-21
CO2018001524A2 (es) 2018-07-10
LUC00301I2 (https=) 2025-09-22
ES2814550T3 (es) 2021-03-29
CL2018000431A1 (es) 2018-11-23
HUS2300011I1 (hu) 2023-03-28
EP3337824A1 (en) 2018-06-27
JP2025013894A (ja) 2025-01-28
US20170051068A1 (en) 2017-02-23
PT3337824T (pt) 2020-09-10
AU2016308567B2 (en) 2022-10-27
KR102890745B1 (ko) 2025-11-26
CN108350076A (zh) 2018-07-31
TW201718651A (zh) 2017-06-01
BR112018003017A2 (pt) 2018-09-25
CY2023007I2 (el) 2023-11-15
FR23C1011I1 (fr) 2023-04-14
UY40513A (es) 2023-11-30
RS60755B1 (sr) 2020-10-30
TWI811023B (zh) 2023-08-01
JP2023027228A (ja) 2023-03-01
IL298041B2 (en) 2025-10-01
MX2022006650A (es) 2022-07-05
UY36859A (es) 2017-04-28
HUE050556T2 (hu) 2020-12-28
US10072088B2 (en) 2018-09-11
EP3757131A1 (en) 2020-12-30
AR134557A2 (es) 2026-01-28
CA2995754A1 (en) 2017-02-23
HRP20201375T1 (hr) 2020-11-27
IL298041B1 (en) 2025-06-01
NZ739862A (en) 2025-05-02
MY191325A (en) 2022-06-15
EA201890513A1 (ru) 2018-11-30
UA127515C2 (uk) 2023-09-20
FR23C1012I2 (fr) 2025-01-10
ZA201801789B (en) 2019-10-30
NL301219I2 (nl) 2023-04-04
EP3337824B1 (en) 2020-06-03
MX2018002043A (es) 2018-07-06
SV2018005634A (es) 2018-06-26
IL257468B2 (en) 2023-06-01
LT3337824T (lt) 2020-09-25
SI3337824T1 (sl) 2020-10-30
DK3337824T3 (da) 2020-08-24
JO3799B1 (ar) 2021-01-31
MA53750A (fr) 2021-09-15
JP7194240B2 (ja) 2022-12-21
PE20180795A1 (es) 2018-05-09
LTPA2023509I1 (https=) 2023-03-10
KR20180040671A (ko) 2018-04-20
LTC3337824I2 (https=) 2024-10-25
CN108350076B (zh) 2022-06-07
KR20250007058A (ko) 2025-01-13

Similar Documents

Publication Publication Date Title
NI201800027A (es) Anticuerpos anti-bcma, moléculas de unión a antígenos biespecíficas que se unen a bcma y cd3, y usos de estos.
CL2024001015A1 (es) Anticuerpos gprc5d, moléculas de unión al antígeno biespecíficas que se unen a gprc5d y cd3, y usos de estas.
CO2018005695A2 (es) Anticuerpos anti-il1rap, moléculas de unión a antígenos biespecíficas que se unen a il1rap y cd3, y usos de estas
NI201700025A (es) Agentes de unión a cd123 y usos de estos.